← 홈

전체 프로그램

ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 306개
CGTBiologicstaleTcelltech Inc.sPhase 1

Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell, Anti-B7-H3 Chimeric Antigen Receptor T-Cell, Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103)

Solid Tumors · B7-H3

#B7-H3#CGT#Phase1#인기#세포유전치료+5
효능 ORR 67%임상시험 63상태 RECRUITING
CGTBiologicstaleEpicentRx, Inc.Phase 2

Checkpoint Inhibitor, Immune (Checkpoint Inhibitor, Immune)

Solid Tumor, Adult; Cancer · Solid Tumor, Adult

#SolidTumorAdult#CGT#Phase2#인기#세포유전치료+5
효능 ORR 59%임상시험 60상태 RECRUITING
CGTBiologicstaleTurnstone Biologics, Corp.Phase 1

RT-01 (Oncolytic Virus Injection, Oncolytic Virus Injection(RT-01))

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#CGT#Phase1#인기#세포유전치료+4
효능 ORR 28%임상시험 60상태 ACTIVE
ADCBiologicBioNTech SEPhase 2

Paroxetine (Paroxetine)

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase2#인기#항체약물접합체+2
임상시험 60상태 RECRUITING
AntibodystaleSun Yat-sen Universityvedotin combined with immun…Phase 3

Serplulimab (Serplulimab)

Colorectal Cancer; Liver Metastases · Solid Tumor Cancer

#SolidTumorCancer#Antibody#Phase3#인기#항체+5
임상시험 60상태 RECRUITING
ADCBiologicAscendis Pharma Endocrinology D…Preclinical

Targeted drugs (Targeted drugs)

Immune-related Adverse Event; Malignant Solid Tumors · Immune-related Adverse Event

#Immune-relatedAdverseEvent#ADC#Preclinical#인기#항체약물접합체+4
효능 ORR 15%임상시험 60상태 RECRUITING
CGTBiologicstaleSabz BiomedicalsPhase 2

cytokine-induced killer cell (cytokine-induced killer cell)

Colon Cancer Stage IV · Solid Tumors

#SolidTumors#CGT#Phase2#인기#세포유전치료+5
임상시험 60상태 ACTIVE
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, ipilimumab + nivolumab)

Solid Tumor; Non Small Cell Lung Cancer · Solid Tumor

#SolidTumor#Antibody#Phase2#인기#항체+4
효능 ORR 77.8%임상시험 60상태 RECRUITING
ADCBiologicAtreca, Inc.vedotin (BV), an anti-CD30 …Preclinical

PD-1 and PD-L1 inhibitor (PD-1 and PD-L1 inhibitor)

Immune-related Adverse Event; Malignant Solid Tumors · PD-1

#PD-1#ADC#Preclinical#인기#항체약물접합체+5
효능 ORR 59%임상시험 59상태 RECRUITING
ADCBiologicstaleStrata OncologyPhase 2

encorafenib + binimetinib (encorafenib + binimetinib)

Cancer; Advanced Solid Tumor · Cancer

#Cancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 66.7%임상시험 48상태 DISCONTINUED
CGTBiologicGuangzhou FineImmune Biotechnol…Phase 1

tumor-specific TCR-T cells (tumor-specific TCR-T cells)

Solid Tumor · Solid Tumor

#SolidTumor#CGT#Phase1#세포유전치료#CAR-T+3
효능 ORR 50%임상시험 45상태 RECRUITING
ADCBiologicstaleSichuan Baili Pharmaceutical Co…viaPhase 2

BL-B01D1 (BL-B01D1)

Rare Malignant Neoplasm; Advanced Solid Tumors · Rare Malignant Neoplasm

#RareMalignantNeoplasm#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
임상시험 44상태 RECRUITING
ADCBiologicCullinan Therapeutics Inc.Deruxtecan-Dlnk Quantificat…Phase 1

Dato-DXd (Datopotamab deruxtecan-dlnk, Datopotamab deruxtecan-dlnk (Dato-DXd))

Advanced Solid Tumor; NSCLC · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 79%임상시험 39상태 RECRUITING
AntibodystaleAnaveon AGVedotin ± Pe…Phase 2

KEYTRUDA® (ANV600 + pembrolizumab, ANV600 + pembrolizumab (KEYTRUDA®))

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#항체#면역항체+4
효능 ORR 71.4%임상시험 31상태 RECRUITING
ADCBiologicstaleBeOne MedicinesPhase 1

Anticancer Agents (Anticancer Agents)

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
효능 0%임상시험 31상태 RECRUITING
AntibodystaleGilead SciencesPhase 2

Magrolimab (Magrolimab)

Solid Tumor; Colorectal Cancer · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+4
효능 ORR 66.7%임상시험 30상태 DISCONTINUED
CGTBiologicstaleShanghai Cell Therapy Group Co.…Phase 1

Fast CAR T cells (Fast CAR T cells)

Solid Tumor · Solid Tumor

#SolidTumor#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 28상태 RECRUITING
ADCBiologicstaleTaiho Oncology, Inc.Phase 2

Futibatinib (Futibatinib)

Advanced Solid Tumor · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 47.1%임상시험 23상태 RECRUITING
CGTBiologicstaleUTC Therapeutics Inc.Phase 1

anti-mesothelin CAR-T cells (anti-mesothelin CAR-T cells)

Solid Tumor, Adult · Solid Tumor, Adult

#SolidTumorAdult#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 23상태 ACTIVE
ADCBiologicstaleHansoh BioMedical R&D CompanyPhase 2

HS-20093 (HS-20093)

Advanced Solid Tumor · Metastatic Colorectal Cancer (CRC)

#MetastaticColorectalCancerCRC#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 22상태 RECRUITING

2 / 16 페이지

← 이전다음 →